May Buying Ventyx Biosciences Ship Eli Lilly Inventory Hovering in 2026?

• Eli Lilly is getting its palms on a promising pipeline candidate due to an acquisition.

• The inventory could not acquire rather more this yr than it already has due to this information.

• Eli Lilly has made a number of comparable strikes in recent times.

• 10 shares we like higher than Eli Lilly ›

Eli Lilly (NYSE: LLY) has been on a roll in recent times, due to its management within the weight administration drug market. Nonetheless, what occurs after its present crop of ani-obesity medicines loses patent exclusivity? That will not be anytime quickly, however contemplating how essential they’re to top-line progress, traders need assurances that Eli Lilly is planning for all times after Zepbound years upfront. That is why one of many firm’s latest acquisitions might be a giant deal.

Eli Lilly just lately agreed to purchase Ventyx Biosciences (NASDAQ: VTYX), a smaller drugmaker, for $1.2 billion in money. Ventyx focuses on creating medicines throughout a number of therapeutic areas, together with neurodegenerative ailments in addition to autoinflammatory and cardiovascular ailments. One among its main candidates is VTX3232, which has produced encouraging mid-stage outcomes. In a single research in overweight sufferers with cardiovascular threat elements, VTX3232 decreased the cardiovascular threat even with out inducing weight reduction.

When paired with semaglutide (Wegovy), VTX3232 demonstrated important reductions in numerous markers of irritation and cardiovascular threat in comparison with semaglutide alone. In different phrases, it might be paired with GLP-1 medicines, particularly to assist sure sufferers at excessive threat of cardiovascular occasions. This investigational medication additionally confirmed promising leads to a section 2 scientific trial for Parkinson’s illness.

Eli Lilly’s shares gained on the information of this acquisition. It is unlikely that upcoming information readouts will jolt the inventory considerably greater than that. Nonetheless, this acquisition highlights, as soon as once more, that Eli Lilly is doing precisely what it’s presupposed to do. The corporate is utilizing its success in weight administration to broaden its pipeline and reduce its publicity to this market. It is not the one transfer Eli Lilly has made just lately. Over the previous couple of years, it has made a number of acquisitions and licensing agreements, strengthening its portfolio.

For example, final yr, Eli Lilly acquired SiteOne Therapeutics, which had a promising non-opioid oral ache inhibitor in its pipeline, thereby increasing its footprint on this space. Eli Lilly additionally acquired Verve Therapeutics, a gene-editing specialist creating medicines for sufferers with a excessive cardiovascular threat.

Elsewhere, the corporate is making a push in oncology. Now, Eli Lilly’s Zepbound and Mounjaro — which share the identical lively ingredient, tirzepatide — will nonetheless be its largest progress drivers for the foreseeable future. However as soon as that tailwind ends, or as competitors in weight administration intensifies, Eli Lilly ought to be capable of overcome these obstacles. That is an essential cause Eli Lilly’s shares are price shopping for.

Before you purchase inventory in Eli Lilly, take into account this:

The Motley Idiot Inventory Advisor analyst crew simply recognized what they imagine are the 10 finest shares for traders to purchase now… and Eli Lilly wasn’t one in every of them. The ten shares that made the reduce might produce monster returns within the coming years.

Take into account when Netflix made this record on December 17, 2004… in the event you invested $1,000 on the time of our suggestion, you’d have $474,578!* Or when Nvidia made this record on April 15, 2005… in the event you invested $1,000 on the time of our suggestion, you’d have $1,141,628!*

Now, it’s price noting Inventory Advisor’s complete common return is 955% — a market-crushing outperformance in comparison with 196% for the S&P 500. Do not miss the most recent prime 10 record, accessible with Inventory Advisor, and be a part of an investing group constructed by particular person traders for particular person traders.

See the ten shares »

*Inventory Advisor returns as of January 17, 2026.

Prosper Junior Bakiny has positions in Eli Lilly. The Motley Idiot has no place in any of the shares talked about. The Motley Idiot has a disclosure coverage.

May Buying Ventyx Biosciences Ship Eli Lilly Inventory Hovering in 2026? was initially printed by The Motley Idiot

• Eli Lilly is getting its palms on a promising pipeline candidate due to an acquisition.

• The inventory could not acquire rather more this yr than it already has due to this information.

• Eli Lilly has made a number of comparable strikes in recent times.

• 10 shares we like higher than Eli Lilly ›

Eli Lilly (NYSE: LLY) has been on a roll in recent times, due to its management within the weight administration drug market. Nonetheless, what occurs after its present crop of ani-obesity medicines loses patent exclusivity? That will not be anytime quickly, however contemplating how essential they’re to top-line progress, traders need assurances that Eli Lilly is planning for all times after Zepbound years upfront. That is why one of many firm’s latest acquisitions might be a giant deal.

Eli Lilly just lately agreed to purchase Ventyx Biosciences (NASDAQ: VTYX), a smaller drugmaker, for $1.2 billion in money. Ventyx focuses on creating medicines throughout a number of therapeutic areas, together with neurodegenerative ailments in addition to autoinflammatory and cardiovascular ailments. One among its main candidates is VTX3232, which has produced encouraging mid-stage outcomes. In a single research in overweight sufferers with cardiovascular threat elements, VTX3232 decreased the cardiovascular threat even with out inducing weight reduction.

When paired with semaglutide (Wegovy), VTX3232 demonstrated important reductions in numerous markers of irritation and cardiovascular threat in comparison with semaglutide alone. In different phrases, it might be paired with GLP-1 medicines, particularly to assist sure sufferers at excessive threat of cardiovascular occasions. This investigational medication additionally confirmed promising leads to a section 2 scientific trial for Parkinson’s illness.

Eli Lilly’s shares gained on the information of this acquisition. It is unlikely that upcoming information readouts will jolt the inventory considerably greater than that. Nonetheless, this acquisition highlights, as soon as once more, that Eli Lilly is doing precisely what it’s presupposed to do. The corporate is utilizing its success in weight administration to broaden its pipeline and reduce its publicity to this market. It is not the one transfer Eli Lilly has made just lately. Over the previous couple of years, it has made a number of acquisitions and licensing agreements, strengthening its portfolio.

For example, final yr, Eli Lilly acquired SiteOne Therapeutics, which had a promising non-opioid oral ache inhibitor in its pipeline, thereby increasing its footprint on this space. Eli Lilly additionally acquired Verve Therapeutics, a gene-editing specialist creating medicines for sufferers with a excessive cardiovascular threat.

Elsewhere, the corporate is making a push in oncology. Now, Eli Lilly’s Zepbound and Mounjaro — which share the identical lively ingredient, tirzepatide — will nonetheless be its largest progress drivers for the foreseeable future. However as soon as that tailwind ends, or as competitors in weight administration intensifies, Eli Lilly ought to be capable of overcome these obstacles. That is an essential cause Eli Lilly’s shares are price shopping for.

Before you purchase inventory in Eli Lilly, take into account this:

The Motley Idiot Inventory Advisor analyst crew simply recognized what they imagine are the 10 finest shares for traders to purchase now… and Eli Lilly wasn’t one in every of them. The ten shares that made the reduce might produce monster returns within the coming years.

Take into account when Netflix made this record on December 17, 2004… in the event you invested $1,000 on the time of our suggestion, you’d have $474,578!* Or when Nvidia made this record on April 15, 2005… in the event you invested $1,000 on the time of our suggestion, you’d have $1,141,628!*

Now, it’s price noting Inventory Advisor’s complete common return is 955% — a market-crushing outperformance in comparison with 196% for the S&P 500. Do not miss the most recent prime 10 record, accessible with Inventory Advisor, and be a part of an investing group constructed by particular person traders for particular person traders.

See the ten shares »

*Inventory Advisor returns as of January 17, 2026.

Prosper Junior Bakiny has positions in Eli Lilly. The Motley Idiot has no place in any of the shares talked about. The Motley Idiot has a disclosure coverage.

May Buying Ventyx Biosciences Ship Eli Lilly Inventory Hovering in 2026? was initially printed by The Motley Idiot